Objectives: To systematically review the impact of antibiotic therapy in the neonatal period on changes in the gut microbiota and/or antibiotic resistance development.
Introduction
Upon birth, infants are suddenly exposed to a wide range of bacteria colonizing mucoepithelial surfaces, including the gut. 1 The subsequent development of the infant gut microbiota is dynamic, non-resilient and shaped by factors such as mode of delivery, feeding, diet and environment. [2] [3] [4] A healthy gut microbiota plays a crucial role in the development of the immune system, digestive functions and protection against infections. [4] [5] [6] The commensal aerobic and anaerobic bacteria are also essential for colonization resistance-the ability to prevent invasion and persistent carriage of pathogenic and antibiotic-resistant bacteria. traditional combination as empirical treatment for neonatal sepsis. 16, 17 Moreover, the emergence worldwide of ESBL-producing Enterobacteriaceae presents major challenges in managing neonatal sepsis. 18 Globally, an estimated 200000 neonatal deaths are attributed to resistant organisms each year. 19 However, the relative impact of different types of antibiotic exposure on the actively developing gut microbiota composition and antibiotic resistance development is not fully understood.
The purpose of this systematic review is to identify, critically appraise and synthesize evidence from studies reporting different categories of antibiotic therapy in neonates and their impact on the gut microbiota and/or antibiotic resistance development. We included both observational studies and randomized controlled trials (RCTs) in line with suggestions from the Cochrane handbook stating that systematic reviews of adverse effects will usually need to include non-randomized studies in addition to RCTs.
Methods
This review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses following a registered protocol and according to the recommendations given by the Cochrane Handbook for Systematic Reviews and Interventions. [20] [21] [22] We recently published a systematic review on early clinical adverse effects of neonatal antibiotic treatment based on the same research protocol. 9 For this review, our primary research question was: 'Are different categories of antibiotic treatment in neonates associated with different changes in gut microbiota composition and/or differences in antibiotic resistance development?' Study protocol registration: PROSPERO CRD42015026743.
Search strategy
We developed our search strategy in consultation with an epidemiologist, a librarian, a paediatric pharmacologist and a neonatologist. We searched PubMed, Embase, Medline and the Cochrane Database using MeSH terms and free-text searches with no time restrictions (last search 22 December 2016). The first search was conducted with MeSH terms in PubMed, Medline and the Cochrane Database by combining 'Infant, Newborn' and 'AntiBacterial Agents' with one of two outcome terms: 'Drug Resistance, Bacterial' or 'Microbiota'. The Embase database uses its own key words, and we combined 'Newborn' and 'Antibiotic Agent' with either 'Antibiotic Resistance' or 'Microbiome'. The second search was conducted using free text in PubMed, Medline and Embase combining the keywords: 'Infant, Low Birth Weight' or 'Infant, Postmature' or 'Infant, Premature' or 'Infant, Newborn' with 'Anti-Bacterial Agents' or 'Antibiotics' and one of the following: 'Antibiotic Resistance' or 'Antibacterial Drug Resistance' or 'Microbiota' or 'Microbiome' or 'Microbiomes' or 'Gut Flora'. We examined reference lists of included studies and relevant reviews to identify additional eligible studies. We then combined all citations and excluded duplicates or triplicates. We did not contact authors for supplementary information and we did not perform searches in the grey literature.
Study selection and eligibility criteria
A study was eligible for review if it reported different categories of intravenous antibiotic treatment in the neonatal period and evaluated their impact on changes in the gut microbiota and/or antibiotic resistance development. If infants were born prematurely we defined the neonatal period as up to 44 weeks postmenstrual age. We compared three different categories of antibiotic therapy: (i) antibiotic treatment yes versus no; (ii) antibiotic treatment long versus short; and (iii) antibiotic treatment broad versus narrow spectrum. For category (ii), we suggested in advance that 'prolonged' antibiotic exposure was always 3 days or the longest regimen among two antibiotic regimens compared. For category (iii), we always defined regimens including third-generation cephalosporins or carbapenems as broad-spectrum regimens when compared with regimens containing aminoglycosides for coverage against Gram-negative bacteria. This definition was based on previous reports indicating that empirical therapy containing a third-generation cephalosporin for Gram-negative coverage induces significantly more resistance than a regimen containing an aminoglycoside. 15 If two similar regimens were compared, the regimen with the broadest spectrum was labelled broad spectrum. Both RCTs and observational studies such as cohort, case-control and cross-sectional studies were eligible for inclusion. We included case-control studies reporting on the prespecified outcomes if data on antibiotic therapy prior to the outcomes were presented as extractable data on cases and controls. We excluded case reports and case series, studies with a non-neonatal or non-human population, studies that were written in languages other than English, and studies that investigated antenatal antibiotics, oral antibiotics and/or low-dose intravenous vancomycin prophylaxis.
Screening, data extraction and management
Two reviewers (J. W. F. and E. E.) independently screened search results and assessed each potentially eligible study per our predetermined inclusion and exclusion criteria. We only excluded studies that we agreed were irrelevant according to our predefined criteria. A third researcher (C. K.) had the deciding vote in cases of disagreement. We extracted the following information from included studies: author, year, country, study design, study population, including gestational age (GA) and birth weight (BW), comparison of outcomes between groups with different categories of antibiotic treatment, and, if available, risk estimates with 95% CI for the specific outcome.
Gut microbiota analyses were based on faecal samples using both standard culture-based methods and culture-independent methods relying on DNA amplification and sequencing. 23 After reviewing the articles presenting data on gut microbiota we decided to present data from these studies in three main categories: microbial load, microbial diversity and microbial composition, clearly acknowledging some overlap between these categories. We defined microbial load as the total number of bacteria in a sample, microbial diversity as the number of different bacterial genera or species in a sample, and microbial composition as the taxonomical composition in a sample. Antibiotic resistance development was based on detection of antibiotic susceptibility patterns in bacteria isolated from blood, urine, cerebrospinal fluid, faeces, tracheal aspirates and/or the skin surface. We defined MDR bacteria as bacteria resistant to 2 unrelated classes of antibiotics or broad-spectrum antibiotics. [24] [25] [26] [27] [28] Included in this category were ESBL-producing Gram-negative bacteria, carbapenem-resistant Acinetobacter baumannii and Gram-negative bacteria resistant to thirdgeneration cephalosporins. Antibiotic-resistant bacteria that did not meet any of these criteria were defined as 'other antibiotic-resistant bacteria'.
We applied a simple vote-counting method to investigate whether the different categories of antibiotic therapy had any effect on the outcomes of interest. 22 Studies were classified based on whether they showed a reduction in the outcome measure, no effect or an increase in the outcome measure following antibiotic treatment. When appropriate, outcomes were presented in vote-count figures.
Assessment of methodological quality
Methodological quality was assessed using the Cochrane Handbook of Systematic Reviews of Interventions and recently published suggestions on how to assess risk of bias and confounding in observational studies. 22, 29 Five domains related to risk of bias were assessed for each study and included: Selection, Performance, Detection, Reporting and Confounding. Risks of bias were judged as low, high or unclear for each domain. The risk of reporting bias was considered unclear in studies that did not have a previously published protocol. The risk of detection bias was considered high in Systematic review studies that examined gut microbiota with culture-based methods, unclear in studies that applied 16S rRNA sequencing techniques and low in studies that applied shotgun metagenome sequencing techniques. Two reviewers (J. W. F. and E. E.) assessed the risks of bias for each study. Disagreements in the categorization process were resolved after discussion between J. W. F., E. E. and C. K.
We applied the Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE) approach to rate the quality of evidence (QoE) for each relevant outcome category. 30 This approach specifies four levels of quality from high to very low, which define the degree to which its estimates of effects or associations can be trusted. 22, 30 RCTs started as high QoE and observational studies started as low QoE. 30 Several factors could either downgrade or upgrade the quality rating.
Results

Overview of included studies
From 3380 identified studies, we reviewed 137 potentially eligible full-text articles. Forty-eight studies met our inclusion criteria: 3 RCTs published between 2000 and 2013, 15, 31, 32 and 45 observational studies published between 1974 and 2016 ( Figure 1) . [24] [25] [26] [27] [28] Two articles presented data from the same study population and were defined as one study. 34, 35 Antibiotic treatment was the randomized intervention in two out of the three included RCTs. 15, 31, 32 Among the 45 observational studies, there were 22 prospective cohort studies, 12 case-control studies, 7 before-after studies and 4 retrospective cohort studies. There were large variations regarding the categories of antibiotic therapy studied. Tables S1 and S2 (available as Supplementary data at JAC Online) display the main characteristics and primary outcomes of interest from the 48 included studies.
Risk of bias and QoE
Figure S1(a and b) displays risk of bias assessments for each included study. Outcomes adjusted for differences in populations were reported in 16/45 (36%) observational studies. 25, 26, 28, 39, 44, 46, 50, 52, 55, 57, 63, 64, 67, [69] [70] [71] Five of these studies used stratification or multivariate analysis to adjust for antenatal antibiotic treatment as a potentially confounding variable. None of the RCTs were included in public registries.
We graded the QoE as very low for the outcomes microbial load and microbial diversity in relation to the three different categories of antibiotic treatment owing to inclusion of observational studies with serious risk of bias and inconsistent results. We graded the QoE as very low for the outcomes relating to microbial composition after antibiotic treatment (Figure 2a-d) . We graded the QoE as moderate for the outcomes relating to antibiotic resistance development owing to inclusion of observational studies that either had large effect sizes (yes versus no and broad versus narrow) or a dose-response effect (long versus short) after antibiotic treatment (Figure 3a -c).
Gut microbiota composition
Nineteen studies reported on antibiotic exposure and impact on the gut microbiota composition (Table S1 ); these comprised 2 RCTs 31,32 and 17 observational studies. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] 73 Three studies reported outcome data from both antibiotic treatment yes versus no and broad versus narrow spectrum, 34, 37, 47 and one study reported outcome after antibiotic treatment yes versus no and long versus short. 42 The remaining 15 studies reported outcome Systematic review JAC data from one category of antibiotic treatment. To examine gut microbiota composition, nine studies used 16S rRNA genesequence analysis, 33, [38] [39] [40] 42, [44] [45] [46] 49 one used fluorescence in situ hybridization techniques, 32 one used deep shotgun metagenome sequence analysis 48 and eight used standard culture-based methods. 31, [34] [35] [36] [37] 41, 43, 47, 73 The included studies reported primarily taxonomic data with different hierarchical details on (i) Enterobacteriaceae, (ii) obligate commensal anaerobic bacteria (bacteroides, lactobacilli and bifidobacteria, etc.), (iii) clostridia and/or (iv) Gram-positive cocci.
Microbial load
Three studies (296 neonates) compared the impact of antibiotic treatment (yes versus no) on microbial loads. 32, 34, 40 One study (165 neonates) found increased microbial loads, 34 one RCT (113 preterm neonates) found decreased microbial loads 32 and one study (18 term neonates) found no significant differences in microbial loads following antibiotic treatment. 40 A small study of extremely low-birth-weight neonates found an inverse correlation between the duration of antibiotic therapy and the microbial load on day 30 of life. 41 (a) Enterobacteriaceae (9 studies; 1407 neonates) Arboleya, 2015 Enterobacteriaceae Abundance 
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Microbial diversity
Four studies (159 neonates) compared microbial diversity after antibiotic treatment (yes versus no). 40, 42, 44, 49 Two studies (112 preterm neonates) reported decreased diversity among antibiotic-treated neonates 42, 49 and two studies (47 neonates) reported no significant differences. 40, 44 Three studies (224 preterm neonates) examined the impact of antibiotic therapy duration (long versus short) on microbial diversity, and all three found decreased diversity following prolonged therapy. 41, 44, 48 Microbial composition Figure 2 displays the results of studies reporting the impact of antibiotic treatment (yes versus no) on microbial composition. Nine studies focused on Enterobacteriaceae; four reported an increase and five studies reported unchanged composition after antibiotic treatment, mainly ampicillin plus an aminoglycoside (Figure 2a) . 33, 34, 36, 37, 40, 42, 43, 46, 47 Five studies focused on different commensal obligate anaerobes, showing a clear trend towards reduced colonization rates following treatment (Figure 2b) . 35, 36, 38, 40, 43 In the five studies focusing on clostridia, there were equivocal results (Figure 2c) . 36, 39, 40, 45, 46 Finally, four studies focused on Gram-positive cocci, and these studies showed either unchanged or higher colonization rates after antibiotic treatment (Figure 2d) . 33, 36, 37, 40 Two studies (n " 983) reported Enterobacteriaceae colonization rates after treatment with broad-versus narrow-spectrum antibiotics. 37, 47 Both studies found lower colonization rates following third-generation cephalosporin treatment. One study of preterm infants (n " 76) reported lower colonization rates of clostridia in those who received 10 days of antibiotic therapy compared with shorter duration. 39 Another study of preterm infants (n " 74) reported higher colonization rates of staphylococci in those who received 5 days of antibiotic treatment compared with shorter-duration therapy. 42 Finally, two studies (n " 104) compared the impact of antibiotic therapy (broad versus narrow) on abundance and/or colonization rates with staphylococci, but neither found any significant differences. 37, 42 Antibiotic resistance development Thirty-one studies, 2 RCTs 15, 31 and 29 observational studies, [24] [25] [26] [27] [28] 37, evaluated the risk of antibiotic resistance development after antibiotic exposure (Table S2) . Five studies reported outcome after antibiotic treatment yes versus no and broad versus narrow spectrum. 27, 37, 53, 55, 67 Two studies reported outcome after antibiotic treatment long versus short duration and broad versus narrow spectrum. 26, 64 Two studies reported outcome after antibiotic treatment yes versus no and long versus short duration. 25, 57 The remaining 23 studies assessed only one category of antibiotic therapy.
Nine studies reported on both infections and colonization with antibiotic-resistant bacteria, 24 MDR Gram-negative bacteria Figure 3 displays the results of the 20 studies reporting the impact of antibiotic exposure on rates of infection and/or colonization with MDR Gram-negative bacteria. Nine studies reported data after antibiotic treatment yes versus no, and the majority reported increased rates of MDR Gram-negative bacteria following treatment (Figure 3a) . 25, 27, 55, 57, 59, 63, 67, 69, 70 Five studies reported data after long versus shorter duration of treatment, and the majority found significantly more MDR Gram-negative bacteria after prolonged treatment (Figure 3b) . 25, 26, 56, 57, 64 Thirteen studies reported data after treatment with broadspectrum versus narrow-spectrum antibiotics, and the overwhelming majority reported higher rates of MDR Gram-negative bacteria following treatment with broad-spectrum antibiotics (Figure 3c) . 15 
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Other antibiotic-resistant bacteria
Four studies (n " 1825) compared the impact of antibiotic treatment (yes versus no) on antibiotic-resistant bacteria that were not MDR according to our definition. 37, 52, 53, 66 One study (n " 584) found a higher rate of prior antibiotic treatment in neonates colonized with antibiotic-resistant Escherichia coli and/or Klebsiella pneumoniae. 66 One study (n " 953) found an increased incidence of TEM-1 genes in E. coli strains in neonates following antibiotic therapy. 53 Two studies (n " 288) found no statistically significant associations between antibiotic treatment (yes versus no) and subsequent antibiotic resistance development. 37, 52 Two studies compared the impact of antibiotic therapy duration; 61, 72 one of them (n " 1180) found significantly longer prior antibiotic treatment among neonates colonized with antibiotic-resistant Gram-negative bacteria, 72 whereas the other (unknown number of neonates) found no correlation between the duration of treatment and gentamicin-resistant Gram-negative bacteria. 61 Eight studies (n " 3029) compared the impact of broad-versus narrow-spectrum antibiotic treatment. 31, 37, 53, 54, 60, 62, 68, 72 One RCT (n " 276) found higher colonization rates with ampicillin-resistant A. baumannii following treatment with penicillin and gentamicin compared with ampicillin and gentamicin. 31 One study (n " 440) found a higher rate of both ampicillin and cefuroxime resistance in Gram-negative bacteria following treatment with ampicillin compared with cefuroxime. 62 One study (n " 118) found a higher rate of gentamicin resistance among Gram-negative bacteria following treatment with gentamicin compared with amikacin. 68 The remaining five studies (n " 2195) did not formally test for statistically significant differences when comparing broad-versus narrow-spectrum regimens, 37, 53, 54, 60, 72 although three of these studies (n " 1258) reported increased rates of antibiotic resistance following broad-spectrum therapy.
54,60,72
Discussion
Key findings
To our knowledge, this is the first systematic review to examine antibiotic therapy in neonates and its impact on gut microbiota and/or antibiotic resistance development. The primary findings were the lack of RCTs and large high-quality observational studies and the heterogeneity regarding methodology and outcomes among the included studies. Despite this, there were several salient features in this review.
First, prolonged antibiotic therapy was associated with reduced gut microbial diversity. 41, 44, 48 Decreased gut microbial diversity has been associated with early adverse outcomes such as necrotizing enterocolitis, and may have potential long-lasting consequences such as increased likelihood of obesity and inflammatory diseases. 10, 49, [74] [75] [76] [77] Combined, these findings imply that prolonged exposure to antibiotic treatment in the neonatal period may increase the likelihood of disease, either in the neonatal period or later in life. However, the QoE for this outcome was graded as very low. It is possible that neonatal antibiotic therapy, regardless of treatment length, leads to decreased microbial diversity, but the studies included in this category were small, and two out of four studies did not detect a significant difference. 
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Second, four out of nine studies reported increased abundance and/or colonization rates of Enterobacteriaceae following neonatal antibiotic treatment, whereas none of the studies reported reduced abundance. 33, 34, 36, 37, 40, 42, 43, 46, 47 In the majority of these studies, the empirical regimens consisted of ampicillin and gentamicin. We speculate that intravenous ampicillin also has an impact on Gram-positive gut bacteria despite being mainly secreted through the kidneys, 78 whereas intravenous gentamicin, mainly covering Gram-negative bacteria in the bloodstream, 79 has a very low penetration into the gut. Combined, this may give undue benefits to Gram-negative Enterobacteriaceae. In contrast, thirdgeneration cephalosporin therapy may lead to a relatively lower abundance of Enterobacteriaceae as both Gram-negative and Gram-positive bacteria are within their spectrum of activity. 79 However, the QoE for this outcome was again graded as very low, and even though overgrowth of Enterobacteriaceae in the human gut has previously been associated with necrotizing enterocolitis, inflammatory bowel disease and chronic fatigue syndrome, there is no strong evidence of any causal relationship. 74, 76, [80] [81] [82] Third, antibiotic treatment in the neonatal period was strongly associated with reduced abundance of protective commensal anaerobic bacteria such as bifidobacteria, lactobacilli and/or bacteriodes. 35, 40, 43 These bacteria provide colonization resistance against antibiotic-resistant bacteria and potentially pathogenic bacteria such as Enterobacteriaceae and Clostridium difficile. Moreover, it is well known that bifidobacteria may reduce expression of inflammatory response genes and stimulate genes promoting the integrity of the mucosal barrier. The QoE for this outcome was graded as very low, but our results are in line with findings in adult populations showing decreased diversity, reduced colonization rates of obligate anaerobes and increased colonization rates of Proteobacteria following antibiotic exposure. [83] [84] [85] Furthermore, our findings are biologically plausible as reduced numbers of bifidobacteria and lactobacilli seem to increase the risk of necrotizing enterocolitis in preterm infants with an exaggerated inflammatory response. 82, [86] [87] [88] [89] [90] In adults some studies have found larger changes in the gut microbiota than oral microbiota following antibiotic treatment, with greater resilience in the oral communities. 84, 85 However, we believe that the gut microbiota is of highest clinical relevance, both as the largest reservoir for antibioticresistant bacteria and because the gut is characterized as the motor of multiple organ dysfunction syndrome.
Fourth, all three categories of neonatal antibiotic treatment investigated in this review were clearly associated with an increased risk of antibiotic resistance development, in particular ESBL-producing Gram-negative bacteria and other MDR bacteria. These findings were based on moderate QoE. Antibiotic resistance genes exist even in the absence of antimicrobial drugs. 91, 92 Moreover, overuse of antibiotics may lead to increased antibiotic resistance through several mechanisms. 91, 93 Antibiotics apply a direct selection pressure that gives significant advantages to bacteria expressing resistance genes. 94 Antibiotic treatment also contributes to changes in the human gut-associated resistome, which comprises numerous functional antibiotic resistance genes in the gut microbiota. 95 Gibson et al. 96 recently found that only a fraction of antibiotic resistance genes that are enriched after a specific antibiotic therapy are unique to the particular antibiotic given. Finally, antibiotic treatment appears to reduce colonization resistance against antibiotic-resistant bacteria through the collateral destruction of obligate anaerobic bacteria. 7, 97 An increase in the gut resistome and a decrease in colonization resistance could theoretically increase horizontal transfer of antibiotic resistance genes from commensals to potential pathogens. 98 Although in vivo horizontal transfer between commensals and pathogens in the gut microbiota remains to be shown, there is evidence of exchange of antibiotic resistance genes between environmental bacteria and human pathogens. 99 
Strengths and limitations
The primary strength of this study is our rigorous and sensitive search strategy based on a previously registered search protocol. Additionally, the adverse impact of the developing infant gut microbiota is of great clinical and scientific interest. The main limitations were the lack of RCTs and the diverse study outcomes, which made meta-analysis impossible to perform. Instead, we applied a semi-quantitative vote-counting method to assess the effect of neonatal antibiotic treatment on relevant outcomes. This method has limitations as it usually fails to account for the population size and methodological quality of pooled studies. Nevertheless, vote counting may be an effective method to assess the ranking of outcomes. 100 Moreover, we attempted to improve the method by presenting the differential weight of each study with squares corresponding to sample size.
The majority of studies included were small and there was considerable heterogeneity in study designs, outcomes, categories of antibiotic treatment and methodological quality. Observational studies are prone to biases and confounding, and only a third of the included studies attempted to adjust for confounding through multivariable regression analysis. Evidence from observational studies is usually considered to be of low quality. However, welldesigned observational studies have been shown to provide similar results to RCTs and they can therefore be useful for detecting rare adverse outcomes by allowing larger sample sizes and longer lengths of follow-up than RCTs for lower costs. 101 We used the GRADE approach to assess the QoE. Overall, we graded the QoE as very low for all outcomes presented in the gut microbiota category. In contrast, we considered the QoE to be moderate in the antibiotic resistance category owing to large effect sizes and a doseresponse effect. Based on current evidence we are therefore moderately confident that all types of antibiotic treatment lead to increased rates of antibiotic resistance.
All included studies published prior to 2007 used culture-based techniques to examine the gut microbiota composition. It has been estimated that ,20% of environmental bacteria can be grown in defined growth media. This increases the risk of detection bias in older studies. 102 Sequencing-based techniques also have limitations. Studies relying on 16S rRNA analysis allow only a coarse sorting of bacteria mainly at phylum level. Deep shotgun metagenome sequencing allows for finer distinction at the genus or species level, but it is of crucial importance to standardize sampling and temperature control during the pipeline up to DNA extraction in order to obtain valid results. 103 Moreover bioinformatic presentations are often challenging to understand and interpret.
We also acknowledge that our definition of broad-spectrum and narrow-spectrum antibiotics is somewhat arbitrary as most of the narrow-spectrum regimens covered both Gram-negative and Gram-positive bacteria. However, our study confirms previous Systematic review findings, clearly suggesting that antibiotic regimens containing third-generation cephalosporins or carbapenems are more frequently associated with antibiotic resistance development than regimens with aminoglycosides for Gram-negative coverage. 15, 24, 26, 28, 50, 55, 64, 65, 67, 71 Finally, we decided to exclude studies that only examined antenatal antibiotic treatment, despite the frequent use of intrapartum antibiotic prophylaxis for prevention of neonatal infections and its reported effects on the infant gut microbiota and carriage of antibiotic resistance genes. 104 The focus of this review was neonatal antibiotic treatment given for suspected neonatal infection, and the isolated effects of antenatal antibiotics given to infants who did not receive antibiotics after birth were beyond the scope of this study.
Implications and conclusions
This systematic review highlights the profound impact on the gut microbiota and antibiotic resistance development exerted by antibiotic treatment in neonates. Antibiotic exposure in the neonatal period appears to induce various potentially disease-promoting alterations in the gut microbiota, but the QoE was very low for the outcomes investigated in this review. However, we are moderately confident, based on data from this review, that antibiotic treatment leads to antibiotic resistance development, in particular in Gram-negative bacteria. This clearly threatens current empirical antibiotic regimens and is a finding of great concern.
In conclusion, the findings from this systematic review, along with the findings from our recent systematic review on early adverse outcome of neonatal antibiotic therapy, 9 strongly emphasize the need to reduce unnecessary antibiotic treatment in neonates. Important steps to reduce the burden of neonatal antibiotic therapy include improving preventive measures such as hand hygiene, stopping antibiotic therapy after 36-48 h if infection is only vaguely suspected and there is no growth in the blood culture, and restricting the empirical use of broad-spectrum antibiotic treatment. 105, 106 Funding J. W. F. and E. E. are recipients of funding for their PhD studies from the Northern Norway Regional Health Authority. This study was supported by internal funding. The funding source had no role in the: design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.
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